Mayo clinic tests personalized steroid dosing to tame pneumonia inflammation

NCT ID NCT05334316

Completed Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This study tests a personalized approach to giving the steroid dexamethasone to hospitalized adults with pneumonia. Instead of a standard dose, the amount is adjusted daily based on a blood marker called C-reactive protein (CRP). The goal is to reduce steroid side effects while still controlling inflammation. The trial will enroll 24 participants and compare this tailored strategy to usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexamethasone
What this could lead to: If successful, this approach could reduce steroid side effects and improve recovery for pneumonia patients by giving the right dose at the right time.
What could go wrong: This is a small early-phase trial with only 24 participants, so results may not apply broadly. The personalized dosing strategy may not prove better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA

Contacts and locations

Locations

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.